Patients with advanced cancers are poorly treated with single immunotherapies due to the heterogeneity of the neoantigen profile and evolving cancer immune evasion mechanisms. Combining several immunotherapies can target different stages of the cancer immune cycle at the same time, combining treatments with different mechanisms of action, such as precision immunotherapy can be combined with conventional treatment to kill cancer cells without relying on neoantigens, Achieve more pronounced and longer-lasting therapeutic results. To overcome drug resistance induced by tumor heterogeneity.

• Profesión: Otros
• Miembro desde: 22-03-24
• Última vez online: 22-03-24